Pluri Inc. Common Stock (PLUR) Stock Price

PLURStock

$1.66−68.65%52W

Market Cap$17.91M

P/E—

PEG Ratio—

Div yield—

Beta0.67

PLUR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-67.43%

Price vs S&P 500 (4W)-10.19%

VGM Score27.09

Book Value / Share (Quarterly)$0.21

P/TBV (Annual)1.89x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)131.94%

Cash Flow / Share (Quarterly)$-2.06

Price vs S&P 500 (YTD)-58.84%

Gross Margin (TTM)40.16%

Net Profit Margin (TTM)-10911.81%

EPS (TTM)$-2.89

10-Day Avg Trading Volume0.02M

EPS Excl Extra (TTM)$-2.89

Revenue Growth (5Y)41.83%

EPS (Annual)$-3.56

ROI (Annual)-86.59%

Gross Margin (Annual)98.77%

Net Profit Margin (5Y Avg)-30867.06%

Cash / Share (Quarterly)$0.89

Revenue Growth QoQ (YoY)-37.93%

ROA (Last FY)-58.38%

Revenue Growth TTM (YoY)-20.87%

EBITD / Share (TTM)$-2.83

ROE (5Y Avg)-99.22%

Operating Margin (TTM)-10118.11%

Cash Flow / Share (Annual)$-2.51

P/B Ratio266.82x

P/B Ratio (Quarterly)2.84x

Net Income / Employee (Annual)$-177,800

EV / Revenue (TTM)39.60x

Net Interest Coverage (TTM)-13.22x

ROA (TTM)-79.00%

EPS Growth QoQ (YoY)35.93%

EPS Incl Extra (Annual)$-3.56

Current Ratio (Annual)0.68x

Quick Ratio (Quarterly)0.33x

3-Month Avg Trading Volume0.02M

52-Week Price Return-68.65%

Revenue / Employee (TTM)$2,065,041,000

Tangible BV / Share (Quarterly)$0.21

P/S Ratio (Annual)54.99x

Asset Turnover (Annual)0.01x

52-Week High$5.68

Operating Margin (5Y Avg)-30847.83%

EPS Excl Extra (Annual)$-3.56

CapEx CAGR (5Y)-5.19%

Tangible BV CAGR (5Y)-14.07%

26-Week Price Return-56.18%

Quick Ratio (Annual)0.68x

13-Week Price Return-32.17%

Total Debt / Equity (Annual)250.28x

Current Ratio (Quarterly)0.33x

Enterprise Value$45.77M

Revenue / Share Growth (5Y)10.64%

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-33.61%

Revenue / Employee (Annual)$2,600

Pretax Margin (Annual)-6547.24%

Cash / Share (Annual)$2.61

3-Month Return Std Dev69.75%

Gross Margin (5Y Avg)88.18%

Net Income / Employee (TTM)$-201,100

ROE (Last FY)-21758.33%

Net Interest Coverage (Annual)-16.32x

EPS Basic Excl Extra (Annual)$-3.56

Receivables Turnover (TTM)0.46x

Total Debt / Equity (Quarterly)260.33x

EPS Incl Extra (TTM)$-2.89

Receivables Turnover (Annual)0.48x

ROI (TTM)-61.52%

P/S Ratio (TTM)99.62x

Pretax Margin (5Y Avg)-30867.06%

Revenue / Share (Annual)$0.06

Tangible BV / Share (Annual)$0.32

Price vs S&P 500 (52W)-86.96%

EPS Growth TTM (YoY)35.10%

Year-to-Date Return-47.83%

5-Day Price Return-4.29%

EPS Normalized (Annual)$-3.56

ROA (5Y Avg)-60.85%

Net Profit Margin (Annual)-6407.36%

Month-to-Date Return0.65%

Cash Flow / Share (TTM)$-0.70

EBITD / Share (Annual)$-3.45

Operating Margin (Annual)-6796.93%

LT Debt / Equity (Annual)250.28x

ROI (5Y Avg)-71.37%

LT Debt / Equity (Quarterly)260.33x

EPS Basic Excl Extra (TTM)$-2.89

P/TBV (Quarterly)2.84x

P/B Ratio (Annual)323.05x

Pretax Margin (TTM)-10911.81%

Book Value / Share (Annual)$0.02

Price vs S&P 500 (13W)-34.97%

Beta0.67x

Revenue / Share (TTM)$0.01

ROE (TTM)-53.15%

52-Week Low$1.45

vGradeF

gGradeC

mGradeF

vgmGradeD

PLUR Earnings Surprise History

Q1 25-0.94est. —

Q2 25-1.00est. -0.73

Q3 25-0.65est. -0.74

PLUR Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
PLURPluri Inc. Common Stock	F	C	F	$1.66
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Pluri Inc. Common Stock

Pluri Inc develops cell-based therapeutics using its proprietary 3D cell expansion platform, targeting regenerative medicine, immunotherapy, and hematologic diseases. The company generates revenue through CDMO services while advancing placenta-derived cell therapy candidates for inflammatory and musculoskeletal conditions. Pluri is also exploring applications in cultivated alternative proteins.